Therapix Biosciences Ltd. (TRPX:NASDAQ) Investor Relations Material

Overview

Therapix Biosciences Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals development. Led by a seasoned team of executives and scientists, the company is focused on expanding its portfolio of technologies and assets. The company’s drug development programs are based on tetrahydrocannabinol (THC) and non-psychoactive cannabidiol (CBD). The programs include THX-110 for treating Tourette syndrome and obstructive sleep apnea, THX-160 for pain relief, and THX-210 for treating autism spectrum disorder and epilepsy.

Frequently Asked Questions

What is Therapix Biosciences Ltd.'s ticker?

Therapix Biosciences Ltd.'s ticker is TRPX

What exchange is Therapix Biosciences Ltd. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Therapix Biosciences Ltd.'s headquarters?

They are based in Givatayim, Israel

How many employees does Therapix Biosciences Ltd. have?

There are 11-50 employees working at Therapix Biosciences Ltd.

What is Therapix Biosciences Ltd.'s website?

It is https://therapixbio.com/

What type of sector is Therapix Biosciences Ltd.?

Therapix Biosciences Ltd. is in the Healthcare sector

What type of industry is Therapix Biosciences Ltd.?

Therapix Biosciences Ltd. is in the Biotechnology industry

Who are Therapix Biosciences Ltd.'s peers and competitors?

The following five companies are Therapix Biosciences Ltd.'s industry peers:

- Cynata Therapeutics Limited

- VBI Vaccines, Inc.

- Synlogic

- Merrimack Pharmaceuticals Inc

- Five Prime Therapeutics Inc